Examples include cancers such as malignant melanoma with BRAF variants, ovarian carcinomas with BRCA alterations and non-small cell lung carcinoma, where the list of targeted treatments is ever expanding but already includes EGFR, ALK, ROS-1, NTRK, MET, RET, BRAF, and KRAS (Imyanitov et al. 2021). This evidence concerns the gene BRAF and melanoma.